7 September 2022 - - US-based biotechnology company Sonoma Biotherapeutics, Inc has appointed Jessica Stitt as chief financial officer, the company said.

Stitt has over 20 years of healthcare finance, strategy, and leadership experience and has participated in the execution of nearly USD 2bn in corporate financing transactions.

She will join Sonoma Biotherapeutics' executive leadership team and oversee the company's finance, accounting, information technology, communications, and investor relations functions.

Prior to joining Sonoma Biotherapeutics, Stitt served as chief financial officer at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on diseases of the eye, acquired by Novartis.

Stitt previously served as vice president of Finance and Operations for MyoKardia, Inc., acquired by Bristol Myers Squibb, and prior to that, served as vice president of Finance and Investor Relations for Theravance Biopharma, Inc.

She previously held roles in finance at Nektar Therapeutics, Alkermes, and Blue Cross Blue Shield of Massachusetts. Stitt holds an MBA from Simmons School of Management and a B.A. from Saint Anselm College.

Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.

Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies designed to cure autoimmune and inflammatory diseases.

Sonoma Biotherapeutics is based in South San Francisco and Seattle.